Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Semaglutide

Ozempic, Rybelsus, Wegovy

Quick Stats
Studies 78
Trials 100
Unknown NA INTERVENTIONAL NCT05779644

Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

The purpose of this study is to analyze the effects of GLP-1RA on blood glucose, body weight, glucose and lipid metabolism and fat distribution in overweight/obese patients with type 2 diabetes mellitus.

Detailed Description

Specific research contents: To study the characteristics of glucose and lipid metabolism and fat distribution in overweight/obesity patients with type 2 diabetes mellitus; liraglutide/ semaglutide/ metformin will be applied to patients for one year, and the changes of lipid metabolism and fat distribution in overweight/obese patients with type 2 diabetes and the differences among the three groups will be analyzed before and after treatment. The metabolomic changes of overweight/obese patients with type 2 diabetes before and after medication and the differences among the three groups will be analyzed. Explore the correlation between visceral fat content, glucose and lipid metabolism, inflammatory factors and other biochemical indicators and metabolomics.

Interventions

Name: Liraglutide
Type: DRUG
Description: Liraglutide is injected once a day.
Name: Semaglutide
Type: DRUG
Description: Semaglutide is injected once a week.
Name: Metformin
Type: DRUG
Description: Metformin is taken orally daily.

Primary Outcomes

Measure: Blood glucose
TimeFrame: The twelfth week of treatment
Description: Glucose metabolism index
Measure: Blood insulin
TimeFrame: The twelfth week of treatment
Description: Glucose metabolism index
Measure: Total cholesterol
TimeFrame: The twelfth week of treatment
Description: Lipid metabolism index
Measure: Triglyceride
TimeFrame: The twelfth week of treatment
Description: Lipid metabolism index
Measure: Lipoprotein
TimeFrame: The twelfth week of treatment
Description: Lipid metabolism index
Measure: Weight
TimeFrame: The twelfth week of treatment
Description: Measure fasting weight
Measure: Abdominal fat distribution
TimeFrame: The twelfth week of treatment
Description: Use Magnetic resonance imaging-proton density fat fraction to measure fat accumulation in the liver, pancreas and abdomen.

Trial Information

NCT ID

NCT05779644

Status

Unknown

Study Type

INTERVENTIONAL

Phases

NA

Sponsor

RenJi Hospital

Last Updated

December 15, 2025